Evidence suggests that adoption of oncology biosimilars in Medicare value-based payment models has produced substantial cost ...

The FDA approved Teva’s biosimilar for denosumab, and the FDA and EMA accepted its asthma biosimilar application for review.

All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...

All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...

All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...

All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...

All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...

All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...

After much anticipation, the FDA approves the first interchangeable biosimilar, which is hoped to bring down the high cost of insulin. The FDA has approved Biocon Biologic's Semglee insulin glargine ...

Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory ...

While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more ...

FDA's new guidance streamlines biosimilar development, reducing costs and regulatory hurdles and potentially enhancing market access and affordability. The FDA has issued draft guidance that ...